HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

sulfated lactosyl archaeol

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jia, Yimei: 4 articles (02/2021 - 11/2019)
2.	McCluskie, Michael J: 4 articles (02/2021 - 11/2019)
3.	Agbayani, Gerard: 3 articles (02/2021 - 11/2019)
4.	Akache, Bassel: 3 articles (02/2021 - 11/2019)
5.	Deschatelets, Lise: 3 articles (02/2021 - 11/2019)
6.	Dudani, Renu: 3 articles (02/2021 - 11/2019)
7.	Krishnan, Lakshmi: 3 articles (02/2021 - 11/2019)
8.	Stark, Felicity C: 3 articles (02/2021 - 11/2019)
9.	Chandan, Vandana: 2 articles (02/2021 - 02/2021)
10.	Harrison, Blair A: 2 articles (02/2021 - 02/2021)

Related Diseases

1.	Neoplasms (Cancer) 10/26/2022 - "Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. " 02/02/2021 - "Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. " 11/23/2019 - "Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA-OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. " 02/12/2021 - "Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model."
2.	Melanoma (Melanoma, Malignant) 11/23/2019 - "Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA-OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. " 02/12/2021 - "Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model."
3.	Communicable Diseases (Infectious Diseases) 10/26/2022 - "Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. " 02/02/2021 - "Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. "
4.	Schistosomiasis (Bilharziasis) 01/01/2020 - "Adjuvanted Schistosoma mansoni-Cathepsin B With Sulfated Lactosyl Archaeol Archaeosomes or AddaVax™ Provides Protection in a Pre-Clinical Schistosomiasis Model."

Related Drugs and Biologics

1.	Vaccines
2.	Poly I-C
3.	Peptides (Polypeptides)
4.	Glycolipids
5.	Vaccine Adjuvants
6.	Proteins (Proteins, Gene)
7.	Cathepsin B
8.	Antigens

Related Therapies and Procedures

1.	Therapeutics